AR071823A1 - Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. - Google Patents
Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos.Info
- Publication number
- AR071823A1 AR071823A1 ARP090101778A ARP090101778A AR071823A1 AR 071823 A1 AR071823 A1 AR 071823A1 AR P090101778 A ARP090101778 A AR P090101778A AR P090101778 A ARP090101778 A AR P090101778A AR 071823 A1 AR071823 A1 AR 071823A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heterocyclyl
- cycloalkyl
- heteroaryl
- cycloalkenyl
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000009424 thromboembolic effect Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 22
- 125000001072 heteroaryl group Chemical group 0.000 abstract 20
- 125000000623 heterocyclic group Chemical group 0.000 abstract 19
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 17
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 16
- -1 heterocyclynyl Chemical group 0.000 abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 abstract 13
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula 1 o su sal, solvato o ester aceptable para uso farmaceutico; donde el anillo A que comprende los tomos del anillo X e Y como se muestra es un anillo de heteroarilo; X es N o NR; Y es N, NR, O u S; L se selecciona del grupo formado por un enlace covalente -C(=O)N(R)-, -N(R)-C(=O)-, -S(=O)2NR- y -N(R)S(=)2-; Q es NR, S u O; cada R es independientemente H, alquilo, haloalquilo, cicloalquilo heterociclilo, arilo, heteroarilo, o -(CR5R6)nW, donde W se selecciona del grupo formado por cicloalquilo, heterociclilo, arilo, heteroarilo, -C(=O)NR5R5, C(=O)OR4, -OR4, -NR5R6; R1 se selecciona del grupo formado por cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, y heteroarilo, en el cual cuando cada uno de dicho anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo contiene sustituyentes en tomos de carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, o heteroarilo de cinco a seis miembros, R2 y R3 se seleccionan en forma individual e independiente del grupo formado por H, alquilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, halo, hidroxi, alcoxi, haloalquilo, y ariloxi, en el cual cuando a uno de dichos cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, heteroarilo, o la porcion arilo de ariloxi contiene sustituyentes en tomos carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse forma en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, o heteroarilo de cinco a seis miembros; o R2 y R3 junto con los tomos de carbono a los cuales se muestra que est n unidos forman un anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo de cinco a seis miembros, en el cual cuando cada uno de dicho anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo contiene sustituyentes en tomos de carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo de cinco a seis miembros; n es 0-2; y Z se selecciona del grupo formado por H, halogeno, alquilo, -OR4, -NR5R6, -NR5C(O)R6, -NR5C(O)OR6, -NR5C(O)NR5R6, -NR5S(O)2R6, -NR5S(O)2N(R6)2; cada R4 se selecciona independientemente del grupo formado por H, alquilo, -C(=O)-heterociclilo, -C(=O)NHalquilo, y -C(=O)N(alquilo)2; cada R5 y R6 se selecciona independientemente del grupo formado por H alquilo, -C(=O)alquilo, y -C(=O)Oalquilo; con la condicion de que el compuesto de formula 1 no sea como se muestra en las formulas (4) o (5). Reivindicacion 49: Un compuesto de formula (2) o su sal, solvato o ester aceptable para uso farmaceutico; donde: el anillo B que comprende los tomos del anillo X1 e Y1 como se muestra es un anillo de heteroarilo; X1 es N o NR; Y1 es N, NR, O u S; L1 se selecciona del grupo formado por -C(=O)N(R)-, -N(R)-C(=O)-, -S(=O)2NR- y -N(R)S(=O)2-; cada R es independientemente H o alquilo; R10 se selecciona del grupo formado por cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, y heteroarilo, en el cual cuando cada uno de dicho anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo contiene sustituyentes en tomos de carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, o heteroarilo de cinco a seis miembros; R11 se selecciona del grupo formado por cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, y heteroarilo, en el cual cuando cada uno de dicho anillo de cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo o heteroarilo contiene sustituyentes en tomos de carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, o heteroarilo de cinco a seis miembros; m es 0-2; Z1 se selecciona del grupo formado por -OR4, -NR5R6, -NR5C(O)R6, -NR5C(O)OR6, -NR5C(O)NR5R6; -NR5S(O)2R6, -NR5S(O)2N(R6)2; R4 es H o alquilo; y cada R5 y R6 se selecciona independientemente del grupo formado por H y alquilo, con la condicion de que: (i) cuando R11 es fenilo, dicho fenilo est no sustituido o sustituido con grupos que no son -(C=NR)NR2, y (ii) cuando L1 es -N(R)C(=O)- el cual est enlazado al anillo B por medio del tomo de nitrogeno, R11 es diferente a fenilo no sustituido. Reivindicacion 79: Un compuesto de formula (3) o su sal, solvato o ester aceptable para uso farmaceutico; donde R15 es arilo, en el cual cuando dicho arilo contiene dos sustituyentes en tomos de carbono adyacentes, dichos sustituyentes pueden opcionalmente tomarse en forma conjunta con los tomos de carbono a los cuales est n unidos para formar un cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, arilo, o heteroarilo de cinco a seis miembros; R16 se selecciona del grupo formado por un heteroarilo de 5 o 6 miembros el cual est fusionado a un anillo de benceno, una quinolin-2-ona, y un fenilo el cual est fusionado a un heteroarilo de 5 o 6 miembros; con la condicion de que cuando R16 es fenilo fusionado a un anillo de piridina, entonces R15 es un arilo no sustituido; y cada uno de R17 y R18 es independientemente H o alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5431008P | 2008-05-19 | 2008-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071823A1 true AR071823A1 (es) | 2010-07-14 |
Family
ID=41066042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101778A AR071823A1 (es) | 2008-05-19 | 2009-05-18 | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8148363B2 (es) |
| EP (2) | EP2300435A2 (es) |
| JP (1) | JP5504259B2 (es) |
| CN (1) | CN102099340A (es) |
| AR (1) | AR071823A1 (es) |
| CA (1) | CA2724430A1 (es) |
| CL (1) | CL2009001214A1 (es) |
| MX (1) | MX2010012635A (es) |
| PE (1) | PE20091972A1 (es) |
| TW (1) | TW201008930A (es) |
| WO (1) | WO2009143039A2 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596488A (en) | 2009-06-26 | 2012-11-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CA2803695A1 (en) * | 2010-06-28 | 2012-01-05 | Bayer Intellectual Property Gmbh | Heteroaryl-substituted pyridine compounds for use as pesticides |
| DK2588465T3 (en) | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
| CN107266433A (zh) | 2010-11-09 | 2017-10-20 | 铁木医药有限公司 | sGC刺激剂 |
| EP2702052B1 (en) | 2011-04-28 | 2017-10-18 | Novartis AG | 17alpha-hydroxylase/c17,20-lyase inhibitors |
| WO2013009527A2 (en) | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
| CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
| US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
| WO2014099695A1 (en) * | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| EP2934536B1 (en) * | 2012-12-19 | 2017-09-27 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| CA2902431A1 (en) | 2013-03-15 | 2014-09-25 | Kevin Michael Short | Halogenopyrazoles as inhibitors of thrombin |
| BR112015022340A2 (pt) * | 2013-03-15 | 2017-07-18 | Verseon Corp | método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica |
| US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| CA2960275A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Smyd inhibitors |
| US10300154B2 (en) | 2014-09-17 | 2019-05-28 | David R Elmaleh | Anticoagulant derivatives for cardiovascular imaging |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| US10314820B2 (en) | 2014-12-04 | 2019-06-11 | Procomcure Biotech Gmbh | Imidazole-based heterocyclic compounds |
| US10456379B2 (en) | 2014-12-04 | 2019-10-29 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
| EP3258929B1 (en) * | 2015-02-16 | 2022-04-27 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| AU2017247798C1 (en) * | 2016-04-07 | 2020-08-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US10975287B2 (en) * | 2016-04-07 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US11014920B2 (en) | 2016-11-18 | 2021-05-25 | Merck Sharp & Dohme Corp. | Factor XIIa inhibitors |
| US11040947B2 (en) | 2017-03-22 | 2021-06-22 | The Research Foundation For The State University Of New York | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors |
| PL3781558T3 (pl) | 2018-04-17 | 2023-05-02 | The Regents Of The University Of Michigan | Inhibitory funkcji płytek krwi i sposoby ich zastosowania |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| TW202220973A (zh) | 2020-08-06 | 2022-06-01 | 美商迦舒布魯姆生物有限公司 | 雜環glp-1促效劑 |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| WO2022078407A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
| CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| EE200100006A (et) | 1998-07-06 | 2002-06-17 | Bristol-Myers Squibb Company | Bifenüülsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| MXPA02012447A (es) | 2000-06-15 | 2003-04-25 | Schering Corp | Antagonistas receptores de trombina. |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| AR036832A1 (es) | 2001-10-18 | 2004-10-06 | Schering Corp | Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos |
| BR0213562A (pt) * | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| PT1495018E (pt) | 2002-04-16 | 2008-02-19 | Schering Corp | Antagonistas tricíclicos de receptores de trombina |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| EP1765335B1 (en) * | 2004-07-07 | 2009-11-25 | Merck & Co., Inc. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
| DE602005021494D1 (de) * | 2004-07-22 | 2010-07-08 | Merck Sharp & Dohme | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
| JP5063351B2 (ja) * | 2004-09-17 | 2012-10-31 | エグゼリクシス， インコーポレイテッド | ピラゾールキナーゼモジュレーターおよび使用方法 |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| CA2724294A1 (en) * | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
-
2009
- 2009-05-18 EP EP09751268A patent/EP2300435A2/en not_active Ceased
- 2009-05-18 EP EP14173412.9A patent/EP2805939B1/en not_active Not-in-force
- 2009-05-18 PE PE2009000694A patent/PE20091972A1/es not_active Application Discontinuation
- 2009-05-18 JP JP2011510610A patent/JP5504259B2/ja not_active Expired - Fee Related
- 2009-05-18 MX MX2010012635A patent/MX2010012635A/es active IP Right Grant
- 2009-05-18 CA CA2724430A patent/CA2724430A1/en not_active Abandoned
- 2009-05-18 US US12/993,607 patent/US8148363B2/en active Active
- 2009-05-18 CL CL2009001214A patent/CL2009001214A1/es unknown
- 2009-05-18 TW TW098116429A patent/TW201008930A/zh unknown
- 2009-05-18 WO PCT/US2009/044291 patent/WO2009143039A2/en not_active Ceased
- 2009-05-18 CN CN200980128238XA patent/CN102099340A/zh active Pending
- 2009-05-18 AR ARP090101778A patent/AR071823A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8148363B2 (en) | 2012-04-03 |
| JP5504259B2 (ja) | 2014-05-28 |
| MX2010012635A (es) | 2010-12-06 |
| WO2009143039A2 (en) | 2009-11-26 |
| CL2009001214A1 (es) | 2010-12-31 |
| EP2805939A1 (en) | 2014-11-26 |
| US20110065682A1 (en) | 2011-03-17 |
| PE20091972A1 (es) | 2010-01-15 |
| EP2805939B1 (en) | 2018-06-27 |
| EP2300435A2 (en) | 2011-03-30 |
| CA2724430A1 (en) | 2009-11-26 |
| TW201008930A (en) | 2010-03-01 |
| CN102099340A (zh) | 2011-06-15 |
| WO2009143039A3 (en) | 2010-07-08 |
| JP2011520967A (ja) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| MX2012015120A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica. | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CY1110232T1 (el) | Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089285A1 (es) | Derivados de betulina | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| CY1122514T1 (el) | Σουλφονικος υδροξυαιθυλεστερας του αναστολεα της εξαρτωμενης απο κυκλινη πρωτεϊνικης κινασης, κρυσταλλικη μορφη αυτου και μεθοδος παρασκευης αυτου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |